MENU
RMD
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

RMD stock forecast, quote, news & analysis

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
RMD
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for RMD with price predictions
Oct 20, 2026

Momentum Indicator for RMD turns positive, indicating new upward trend

RMD saw its Momentum Indicator move above the 0 level on October 07, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 61 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for RMD just turned positive on October 08, 2026. Looking at past instances where RMD's MACD turned positive, the stock continued to rise in 23 of 39 cases over the following month. The odds of a continued upward trend are 59%.

RMD moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RMD crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.

The 50-day moving average for RMD moved above the 200-day moving average on October 08, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where RMD advanced for three days, in 181 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

The Aroon Indicator entered an Uptrend today. In 137 of 218 cases where RMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.

RMD broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 40 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. RMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.378) is normal, around the industry mean (4.940). P/E Ratio (23.448) is within average values for comparable stocks, (36.759). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (4.456). Dividend Yield (0.011) settles around the average of (0.005) among similar stocks. P/S Ratio (5.896) is also within normal values, averaging (56.074).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Dividends

RMD paid dividends on September 24, 2026

ResMed RMD Stock Dividends
А dividend of $0.66 per share was paid with a record date of September 24, 2026, and an ex-dividend date of August 20, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.15B. The market cap for tickers in the group ranges from 126 to 154.74B. ISRG holds the highest valuation in this group at 154.74B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 8%. NXGL experienced the highest price growth at 32%, while NNNN experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 12%. For the same stocks of the Industry, the average monthly volume growth was -43% and the average quarterly volume growth was 14%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 52
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 95
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
RMD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of devices for evaluation and treatment of sleep disorders

Industry PharmaceuticalsOther

Industry
Medical Specialties
Address
9001 Spectrum Center Boulevard
Phone
+1 858 836-5000
Employees
11370
Web
https://www.resmed.com
Momentum Indicator for RMD turns positive, indicating new upward trend